GlySens Incorporated is a privately held corporation committed to developing a long-term glucose sensor system to continuously monitor glucose levels and enhance the care and treatment of diabetes. GlySens’ approach uses a long-term, fully implanted sensor that functions automatically and continuously, transmitting its glucose signal wirelessly to a display or monitor. The sensor enables the introduction of new medical device systems to significantly improve the lives of people living with diabetes.
GlySens’ implantable long-term continuous glucose monitoring sensor is designed to provide an unobtrusive means to continuously track glucose levels and improve the lives of people with diabetes. An initial system release will comprise two elements: the long-lived fully implanted sensor and an external monitor with a display.
The sensor is implanted under the skin and continuously monitors the glucose levels in the subcutaneous tissue, which are correlated to blood glucose levels. The sensor transmits the glucose measurements wirelessly to a convenient external display device. This device shows the current blood glucose level and a historical chart of the previous blood glucose values, provides adjustable automatic warnings of high and low blood glucose readings, and stores information for easy analysis by the user or physician.
Improving therapeutics delivery in diabetes treatment by automating administration of therapeutics and restoring glycemic control to forestall the devastating side effects of the disease is a key goal in the company’s product development. GlySens is specifically designing its sensor as a closed-loop automatic or semi-automatic glucose control device (an “artificial pancreas”) with particular emphasis being paid to the sensor’s ability to detect hypoglycemia. Application of new, ultrafast-acting insulins and other therapeutics could especially benefit from this system.
GlySens uses two sensors that are both incorporated in the implantable device: (1) a glucose sensor in which a selective chemical reaction, involving glucose and oxygen, is monitored by an electrochemical oxygen detector; and (2) an oxygen reference sensor to detect tissue oxygen. Dual sensors help ensure the specificity of the glucose measurement by eliminating the effects of secondary factors such as temperature, blood flow in the surrounding tissues, and long-term changes due to the body’s normal mild encapsulation response to the implant. GlySens believes that its combination of superior technology, user friendly features, and a long-term design will provide major advances for people with diabetes. By serving key roles in upcoming sensor-driven systems, GlySens’ technology may help enable the introduction of new therapeutic tools.
Worldwide, an estimated 347 million people have diabetes, and this number is expected to double by the year 2030. In the U.S., eight percent of the population (26 million people) has diabetes, and a further 79 million people are classified as pre-diabetic. Nearly one in four hundred children has type 1 diabetes and is insulin-dependent, and by age 60 about 23% of the population has type 2 diabetes. The worldwide annual expenditure on home and self blood glucose monitoring products has been estimated at $7 to $10 billion with half of the sales occurring in the U.S. The total economic impact of diabetes in the U.S. is estimated at $198 billion each year.
The GlySens sensor communicates information about glucose levels in the tissues to an external receiver via wireless telemetry. This device is 38mm across and 16 mm thick and it could be implanted subcutaneously at the waist or the lower abdomen by a simple outpatient procedure.
6450 Lusk Boulevard Suite E-109, San Diego, CA 92121
Tel: (858) 638-7708
Fax: (858) 638-7727
Joseph Y. Lucisano, PhD – President, CEO, CTO
Private investments and numerous research and development grants from private and public agencies
David A. Gough, PhD
Jacobs School of Engineering